Efficacy and Safety of Lobeglitazone Versus Sitagliptin

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 248 participants.

Also called NCT02480465

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 248 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT02480465
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT02480465. Randomized; quadruple masking; primary purpose treatment. Start 2015-01 (registry gives no type); primary completion 2016-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Lobeglitazone Versus Sitagliptin
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Lobelitazone 0.5mg
Intervention (Drug)
Sitagliptin 100mg
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct02480465
Content hash
df773669b682eb132b264c33d03ad1095476f16607d32fce4ce0ef2af570c2f8